PTEN deletion or mutation was also reported to increase the sensitivity to AKT inhibitors, PI3K inhibitors, mTOR inhibitors and Hsp90 chaperone inhibitors in breast and other types of cancers 17, 39, 40. This evidence concerns the gene AKT1 and cancer.